If you have been reading about GHK-Cu and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
GHK-Cu is the copper-binding complex formed by the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The free peptide is usually written as GHK, and the complex is written as GHK-Cu or Cu-GHK. The sequence was identified in human plasma and later detected in saliva and urine. Its name comes from the single-letter codes of glycine, histidine and lysine. The complex is widely described as a naturally occurring carrier of copper in blood rather than as a free peptide with its own hormonal role.
Copper binds to the peptide through the histidine imidazole nitrogen and the terminal amino group, forming a stable square-planar complex. Binding constants reported for copper(II) with GHK are high, so the peptide competes effectively for copper in solution. The complex absorbs visible light, which gives solutions a blue to violet colour. Whether the metal-free peptide has a distinct biological function of its own is still an open question; some work treats it mainly as a copper delivery vehicle, while other work reports peptide-specific effects.
Aqueous solutions of GHK-Cu are less stable than the dry powder. The peptide backbone is vulnerable to hydrolysis at extreme pH, and copper can be stripped from the complex by strong chelating agents such as EDTA or citrate. Oxidising agents and high concentrations of ascorbic acid can reduce copper(II) and change the complex, which is one reason formulators often keep such ingredients in separate phases. How quickly these changes occur under real storage conditions depends on pH, buffer, temperature and packaging, and quantitative data on the subject are limited.
Dry material is normally held cold, commonly at -20 °C for long-term storage and 2 to 8 °C for working quantities, protected from light and moisture. Vials should be allowed to reach room temperature before opening so that condensation does not form on the powder. In liquid formulations the complex is generally kept near neutral to slightly acidic pH, because strongly alkaline conditions favour precipitation of copper hydroxide. Antioxidants or chelate-stabilising excipients are often added, though the specific approaches are proprietary and rarely published in detail.
| Property | Value | Notes |
|---|---|---|
| Sequence | Gly-His-Lys | Three amino acids; histidine supplies the main copper-binding nitrogen |
| Bound metal | Copper(II) | Coordination is described as square-planar around the metal centre |
| Appearance | Blue to violet solid | Colour originates from copper d-d electronic transitions |
| Solubility class | Freely soluble in water | Aqueous solutions are often slightly acidic |
| Common synonyms | Copper tripeptide, Cu-GHK | Ingredient lists may say only 'copper peptide' without giving the sequence |
Dry material is typically held at low temperature, often around minus twenty degrees Celsius, and protected from moisture and light. Copper complexes can release their metal ion under acidic conditions or in the presence of competing chelators. Hydrolysis of the peptide backbone is a slower but real pathway, and the histidine residue is susceptible to oxidation over long periods. Stability statements therefore depend on formulation, pH, and container, and they should be read as conditional rather than absolute.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Copper content is measured separately by techniques such as inductively coupled plasma mass spectrometry or atomic absorption. Amino acid analysis confirms the peptide sequence after hydrolysis. Because the metal and the peptide can be quantified independently, a complete certificate of analysis normally reports both values rather than a single purity figure. This separation of measurements is important when comparing suppliers.
Laboratory studies describe GHK-Cu as a source of copper that cells can take up, with reported effects on collagen, elastin, and glycosaminoglycan synthesis in cultured fibroblasts. The peptide also appears in wound-repair research, where it is linked to the activity of matrix metalloproteinases and their inhibitors. These observations come largely from cell and animal models. How directly the complex controls any single pathway in intact human skin remains an open question, and reported effects depend on concentration, vehicle, and exposure time.
Copper takes part in redox chemistry, and the same property that makes it useful in enzymes can generate reactive oxygen species when the ion is loosely bound. GHK chelates copper through imidazole, amino, and amide nitrogen donors, which reduces the amount of free copper in solution. Whether that chelation is protective, neutral, or harmful in a given tissue is not settled. Laboratory assays report both antioxidant and pro-oxidant behavior, depending on the conditions and the readout used.
Published work on GHK-Cu is dominated by in vitro experiments and small animal studies. Human trials tend to be short and small, with endpoints such as skin appearance rather than clinical outcomes. Review articles often summarize the same underlying laboratory findings, which can make the evidence base look broader than it is. Several basic questions remain open: the concentration of the intact complex in human tissue, the route by which it crosses the skin barrier, and whether effects seen in culture produce measurable changes in people.
Medical treatment of gynecomastia that has persisted beyond two years is often ineffective. Gynecomastia is different from "pseudogynecomastia", which is commonly present in men with obesity. Medications such as aromatase inhibitors are effective, even in rare cases of gynecomastia from disorders such as aromatase excess syndrome or Peutz–Jeghers syndrome, but surgical removal of the excess tissue can be needed to correct the condition. In 2019, 24,123 male patients underwent the procedure in the United States, accounting for a 19% increase since 2000.
=== Complications === Pulp acts as a security and alarm system. Slight decay in tooth structure not extending to the dentin may not alarm the pulp, but as the dentin gets exposed, due either to dental caries or trauma, sensitivity starts. The dentinal tubules pass the stimulus to the pulp's odontoblastic layer, triggering the response. This mainly responds to cold. At this stage, simple restoration can be performed. As the decay progresses near the pulp, the response magnifies. Sensation to heat and cold increases. At this stage, indirect pulp capping may be advisable. At this stage it may be impossible to clinically diagnose the extent of decay. Carious dentin by dental decay progressing to the pulp may get fractured during mastication, traumatizing the pulp, resulting in pulpitis. Pulpitis can be painful and may call for root canal therapy or endodontic therapy. Traumatized pulp starts an inflammatory response. The hard and closed surroundings builds pressure inside the pulp chamber, compressing the nerve fibres and eliciting pain. At this stage, the pulp starts to die, progressing to periapical abscess formation (chronic pulpitis). Pulp horns recede with age. The pulp undergoes a decrease in intercellular substance, water, and cells as it fills with collagen fibers. This decrease in cells is evident in the reduced number of undifferentiated mesenchymal cells. The pulp becomes more fibrotic, reducing the regenerative capacity of the pulp due to the loss of these cells.
Evidence of early interest in snake venom was prevalent throughout the early 20th century with one of the first big breakthroughs being in the mid-1960s. For example, Halbert Raudonat was one of the first researchers to fractionate Cobra (Naja nivea) venom using a sophisticated dialysis and paper chromatography techniques. Furthermore, Evert Karlsson and David Eaker were able to successfully purify the specific neurotoxins found in Cobra (Naja nigricollis) venom and found that those isolated polypeptides had a consistent molecular weight of around 7000. Future research in this field would eventually lead to indirect predictive models and then direct crystal structures of important many protein superfamilies. For example, Barbara Low was one of the first to release a 3D structure of the three-finger protein (TFP), Erabutoxin-b. TFPs are an example of α-Neurotoxins, they are small in structure (~60-80 amino acid length) and are a predominant component found in many snake venoms (representing up to 70%-95% of all toxins).
Sources: en.wikipedia.org
In February 2023, French Foreign Minister Catherine Colonna met with President Lula and stated that "Brazil is one of the main actors on the global stage and its comeback is highly expected", highlighting that France and Brazil share a strong, centuries-old relationship. She also said that France supports a Brazilian OECD membership and that both France and the European Union are considering monetary contributions to the Amazon Fund. On 11 February, French president Emmanuel Macron expressed his approval for a peace plan on the Russia-Ukraine war proposed by Lula, which consists of creating a group of countries not involved in the conflict (either directly or indirectly, i.e. by sending weapons to one of the sides) to mediate a peace process. On 3 June 2023, Macron's office said Lula confirmed he would visit Paris in late June as part of the "Summit for a New Global Financial Pact" promoted by France to "tackle the reform of multilateral development banks (MDB), the debt crisis, financing for green technologies, the creation of new international taxes and financing instruments", among other things. On 22 June, president Lula delivered a speech during the Power Our Planet festival in Paris in which he said "actually, those who have polluted the planet over the last two centuries are the same ones who made the Industrial Revolution, and that's why they must pay their debt to the planet Earth" while calling for climate justice to Latin-American, African and Asian peoples and inviting the world to attend the COP30 climate conference in the Brazilian city of Belém.
=== Suspended === Dexmedetomidine (BXCL-501; Igalmi; KalmPen) – α2-adrenergic receptor agonist – alcoholism Rocavorexant (C4X-3256; INDV-2000) – orexin OX1 receptor antagonist – opioid-related disorders Tetrodotoxin (9401-TTX; Halneuron; Tectin; Tetrodin; Tocudin) – voltage-gated sodium channel blocker
Scarborough's drinking water is supplied by the R.C. Harris Filtration Plant at the foot of Victoria Park Avenue and the F. J. Horgan Filtration Plant. The F. J. Horgan Filtration Plant was built in 1979 and was formerly known as the 'Easterly Plant'. Upgrades completed in 2011 allow it to process up to 800 megalitres per day and it will also be the first plant to replace chlorine with ozone as its primary cleansing method. Wastewater for Scarborough is treated at the Highland Creek Treatment Plant. This plant was constructed in 1954 and started processing in 1956. It has undergone continual expansion to meet ongoing demand.
The majority of the population of Jammu and Kashmir is Muslim and a large minority is Hindu. Most Muslims in Jammu and Kashmir belong to the Sunni sect of Islam, especially the Gurjars, Bakarwals, Sayids, Pathans, Sheikhs, Mughals, Paharis, and Doms. As per the 2011 census of India, about 68.3% of people in Jammu and Kashmir were Muslims. Hindu made up around 28.4% of the population. Other small religious groups included Sikhs at 1.9%, Buddhists at 0.9%, and Christians at 0.3%. The population of the Kashmir Division is predominantly Muslim (96.41%) with small Hindu (2.45%) and Sikh (0.81%) communities. Shias are mostly concentrated in the Budgam district, where they form about 30–40% of the population. Among the Kashmiri Hindus, the Pandits are a significant group. The Jammu Division is predominantly Hindu (67.5%) with a significant Muslim population (30%). The Muslims form a majority in the Rajouri (63%), Poonch (90%), Doda (54%), Kishtwar (58%) and Ramban (71%) districts of Jammu, while the Hindus form a majority in Kathua (88%), Samba (86%), Jammu (84%) and Udhampur (88%) districts. Reasi district has an almost equal number of Hindus and Muslims. Most Dogras in the region are Hindus and belong to various Hindu castes. Paharis include both Hindu and Muslims. The Gurjars and Bakarwals are predominantly Sunni Muslims.
Sources: en.wikipedia.org
=== Additional background === Before translation can begin, the process of binding a specific amino acid to its corresponding tRNA must occur. This reaction, called tRNA charging, is catalyzed by aminoacyl tRNA synthetase. A specific tRNA synthetase is responsible for recognizing and charging a particular amino acid. Furthermore, this enzyme has special discriminator regions to ensure the correct binding between tRNA and its cognate amino acid. The first step for joining an amino acid to its corresponding tRNA is the formation of aminoacyl-AMP:
== Pharmacology == The drug potentiates the tropomyosin receptor kinases TrkA, TrkB, and TrkC with EC50Tooltip half-maximal effective concentration values of 382 nM, 295 nM, and ~330 nM, respectively. As a positive allosteric modulator of TrkA and TrkB, ACD856 potentiates the effects of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). In addition to the tropomyosin receptor kinases, ACD856 is also a similarly potent positive allosteric modulator of certain other receptor tyrosine kinases, including the insulin-like growth factor 1 receptor (IGF1R) and the fibroblast growth factor receptor 1 (FGFR1). However, its efficacies at the IGF1R and FGFR1 were much lower than at the TrkA, TrkB, and TrkC. In animals, ACD856 has been found to reverse scopolamine- and dizocilpine (MK-801)-induced memory impairment, to improve age-related memory deficits, and to have sustained antidepressant-like activity. It has also been reported to possess neuroprotective properties. In humans, the drug has been shown to cross the blood–brain barrier and to induce dose-dependent changes in electroencephalogram parameters. No significant tolerability or safety concerns have been identified in preclinical research or phase 1 clinical trials. The drug's clinical pharmacokinetics have been characterized and its elimination half-life is approximately 19 hours.
== Downstream processing == After separation, an additional separation method may then be used, such as isoelectric focusing or SDS-PAGE. The gel will then be physically cut, and the protein complexes extracted from each portion separately. Each extract may then be analysed, such as by peptide mass fingerprinting or de novo peptide sequencing after in-gel digestion. This can provide a great deal of information about the identities of the proteins in a complex.
Sources: en.wikipedia.org
The letters GHK are the one-letter codes for glycine, histidine and lysine, the three amino acids in the peptide. The suffix Cu indicates that the peptide is bound to a copper ion, normally copper(II).
The free tripeptide and its copper complex have been measured in human plasma, saliva, urine and some tissue extracts. Reported concentrations vary widely between studies, and the role of the complex in normal physiology remains partly unresolved.
The plain peptide lacks the metal, so its charge, colour and binding behaviour differ. The copper complex is blue and carries a bound copper ion, while the metal-free form is colourless and has different solution chemistry.
Dry powder is best kept cold, dark and sealed, typically at -20 °C for long-term storage or 2 to 8 °C for material in regular use. Vials should be warmed to room temperature before opening to prevent moisture condensing on the contents. Aqueous stock solutions degrade faster and are usually prepared fresh.